3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Vascular Diseases
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Pathologic Processes
1
Paraproteinemias
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Multiple Myeloma
1
Mullerian Mixed Tumor of Ovary
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Digestive System Neoplasms
1
Interventions
Azacitidine
142
Cytarabine
109
venetoclax
94
fludarabine
35
Daunorubicin
34
Decitabine
32
Idarubicin
26
gilteritinib
24
Cyclophosphamide
21
quizartinib
15
midostaurin
15
Mitoxantrone
14
Etoposide
14
Granulocyte Colony-Stimulating Factor
12
Gemtuzumab
11
CPX-351
11
decitabine and cedazuridine drug combination
10
Drug Therapy
10
cc-486
9
Filgrastim
9
Clofarabine
9
ivosidenib
8
Injections
8
Dexamethasone
8
pevonedistat
7
fludarabine phosphate
7
AP 1903 reagent
7
posaconazole
6
magrolimab
6
glasdegib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Acute
×
ficlatuzumab
×
Clear all
NCT04100330
2020-03-31
CyFi2
AVEO Pharmaceuticals, Inc.
Phase 2
Withdrawn